LeaderPortfolio
Juneja
Rajeev Juneja
Rank #1462
INDIAHealthcarePhamaceuticals

Rajeev Juneja

Net Worth
$2.834B
-0.75% (24h)
Rajeev Juneja, the co-founder of Mankind Pharma, has built a significant net worth through the pharmaceuticals industry. His career began in 1984, and in 1995, he co-founded Mankind Pharma with his brother, Ramesh Juneja. Mankind Pharma is a major player in India's low-cost generics market, generating over $1.05 billion in revenue. Juneja's achievements include building a company recognized for affordable medicines, with popular brands such as Manforce condoms and Prega News. His strategic focus on expansion and innovation has driven the company to become a leading pharmaceutical entity in India.

How to read Rajeev Juneja's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Rajeev Juneja, we anchor the narrative to Phamaceuticals and Phamaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.834B alongside global rank #1462, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (INDIA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Career Beginnings

Rajeev Juneja's journey began in India, where he was born around 1965. He co-founded Mankind Pharma in 1995 with his brother Ramesh Juneja. Juneja's early experiences involved working as a medical representative and gaining experience in the pharmaceutical industry.

Rise to Success with Mankind Pharma

In 1995, Rajeev Juneja and his brother Ramesh co-founded Mankind Pharma with the vision of providing affordable and high-quality medicines. The company initially focused on low-cost generics, a strategy that prioritized volume and accessibility in the Indian market. Mankind Pharma expanded its product portfolio to include consumer health products like condoms and pregnancy test kits, increasing revenue streams and brand recognition.

Key Business Strategies

Mankind Pharma's success is built on several key strategies. The company's emphasis on low-cost generics has allowed it to serve a large customer base, particularly in rural and semi-urban areas. The strategic decision to diversify into consumer health products has further expanded the company's revenue and brand recognition. Furthermore, Mankind Pharma went public in 2023, which has further solidified its position and attracted significant investor interest.

Philanthropy

While specific details on Rajeev Juneja’s philanthropy are not readily available, his commitment to Mankind Pharma’s mission suggests a broader interest in healthcare accessibility. Mankind Pharma's goal of providing affordable medicine points towards a focus on making a positive impact on society.

Career Timeline

2024

Appointed President of PHD Chamber of Commerce and Industry

Appointed President of the PHD Chamber of Commerce and Industry for the policy year 2025-26.

2023

Mankind Pharma IPO

Mankind Pharma went public, marking a significant milestone and further solidifying the company's position in the market.

1995

Co-founded Mankind Pharma

Co-founded Mankind Pharma with his brother Ramesh Juneja, which has grown into a major player in the Indian pharmaceutical market.

Philanthropic Impact

Healthcare$XB

Healthcare Initiatives

Mankind Pharma focuses on providing affordable and quality medicines to millions

Key Business Ventures & Holdings

CompanyStakeValue
Mankind Pharma

Net Worth History

In-Depth Analysis

Early Life and Career Beginnings

Rajeev Juneja's journey began in India, where he was born around 1965. He co-founded Mankind Pharma in 1995 with his brother Ramesh Juneja. Juneja's early experiences involved working as a medical representative and gaining experience in the pharmaceutical industry.

Rise to Success with Mankind Pharma

In 1995, Rajeev Juneja and his brother Ramesh co-founded Mankind Pharma with the vision of providing affordable and high-quality medicines. The company initially focused on low-cost generics, a strategy that prioritized volume and accessibility in the Indian market. Mankind Pharma expanded its product portfolio to include consumer health products like condoms and pregnancy test kits, increasing revenue streams and brand recognition.

Key Business Strategies

Mankind Pharma's success is built on several key strategies. The company's emphasis on low-cost generics has allowed it to serve a large customer base, particularly in rural and semi-urban areas. The strategic decision to diversify into consumer health products has further expanded the company's revenue and brand recognition. Furthermore, Mankind Pharma went public in 2023, which has further solidified its position and attracted significant investor interest.

Philanthropy

While specific details on Rajeev Juneja’s philanthropy are not readily available, his commitment to Mankind Pharma’s mission suggests a broader interest in healthcare accessibility. Mankind Pharma's goal of providing affordable medicine points towards a focus on making a positive impact on society.

Data Sources & Methodology

Figures for Rajeev Juneja are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.